The Hidden Cost of Poor Biostatistical Planning in Early-Phase Trials

Early-phase clinical trials, particularly Phase I and early Phase II, are often seen as exploratory stepping stones. Yet, what happens at these stages can determine the fate of an entire drug development program. At the heart of these early decisions lies biostatistics: the scientific foundation that transforms raw observations into meaningful insight.  Unfortunately, many sponsors underestimate its importance. Poor biostatistical […]